Acalabrutinib Maleate
Brand name: Calquence
Rank #41 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$457.0M
Total Cost
31,890
Total Claims
$457.0M
Total Cost
1,328
Prescribers
$14K
Cost per Claim
490
Beneficiaries
32,065
30-Day Fills
$344K
Avg Cost/Provider
24
Avg Claims/Provider
Share of Medicare Part D Spending
0.17%
of total Medicare Part D spending
$457.0M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $457.0M total
🔎 Data Overview
Ranked #41 out of 500 drugs tracked by total cost. Acalabrutinib Maleate represents a significant portion of Medicare drug spending.
At $14,332 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $344,158 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $932,738 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Acalabrutinib Maleate
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Lindsey Hendrickson | Nurse Practitioner | Charleston, SC | 171 | $2.5M |
| 2 | Brian Hill | Hematology-Oncology | Cleveland, OH | 143 | $2.2M |
| 3 | Randall Davis | Hematology-Oncology | Birmingham, AL | 166 | $2.2M |
| 4 | Adam Kittai | Hematology | New York, NY | 137 | $2.1M |
| 5 | Antoine Chahine | Medical Oncology | Canfield, OH | 123 | $1.9M |
| 6 | Nancy Bartlett | Medical Oncology | Saint Louis, MO | 119 | $1.9M |
| 7 | Carissa Laudati | Nurse Practitioner | Basking Ridge, NJ | 122 | $1.7M |
| 8 | Ian Flinn | Hematology-Oncology | Nashville, TN | 116 | $1.7M |
| 9 | John Winters | Hematology-Oncology | Scarborough, ME | 113 | $1.6M |
| 10 | Tara Graff | Medical Oncology | Des Moines, IA | 112 | $1.6M |
| 11 | Wahid Hanna | Hematology-Oncology | Knoxville, TN | 121 | $1.5M |
| 12 | Jennifer Tran | Nurse Practitioner | Houston, TX | 98 | $1.5M |
| 13 | Alicia Rae Mcleish | Nurse Practitioner | Philadelphia, PA | 105 | $1.5M |
| 14 | Stephen Spurgeon | Hematology-Oncology | Portland, OR | 119 | $1.5M |
| 15 | Manali Kamdar | Hematopoietic Cell Transplantation and Cellular Therapy | Aurora, CO | 103 | $1.4M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 38 | Fluticasone/Vilanterol (Breo Ellipta) | $493.0M | 909,837 |
| 39 | Tiotropium Bromide (Spiriva Handihaler) | $478.1M | 673,800 |
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
| 41 | Acalabrutinib Maleate (Calquence) | $457.0M | 31,890 |
| 42 | Atorvastatin Calcium (Atorvastatin Calcium) | $444.6M | 30,263,929 |
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
| 44 | Levothyroxine Sodium (Levothyroxine Sodium) | $435.3M | 20,209,418 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology